Categoría

HEMATOLOGÍA-ONCOHEMATOLOGÍA

Home > Áreas Terapéuticas > HEMATOLOGÍA-ONCOHEMATOLOGÍA (Page 4)

Casado LF, Hernández JA, Jarque I, Echave M, Casado MA, Castro A

 

 

Cost-utility of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia
20th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Glasgow, Scotland. 4-8 nov 2017

POSTER

Casado LF, Hernandez JA, Jarque I, Echave M, Casado MA, Castro A

 

 

Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia
Eur J Haematol. 2018;100:264–272

Torres C, Oyagüez I, Álvarez MT, Canaro M, Parra R, García JP, Casado MA

 

 

Estimation of annual bleeding management cost in severe haemophilia A patients, without inhibitors, in Spain
World Federation of Hemophilia WFH 2016 World Congress. Orlando, EEUU. 24-28 jul 2016

Sabater E, Oyagüez I, Martin M, Bonanad S, Nuñez R, García JP, Casado MA

 

 

Long-term Health outcomes comparison between prophylaxis and on-demand treatment in patients with severe haemophilia A with factor VIII inhibitors
World Federation of Hemophilia WFH 2016 World Congress. Orlando, EEUU. 24-28 jul 2016

Sabater E, López-Guillermo A, Rueda A, Salar A, Oyagüez I, Collar JM

 

 

Cost-effectiveness analysis of bendamustine plus rituximab as a first-line treatment for patients with follicular lymphoma in Spain
Appl Health Econ Health Policy 2016;14(4):465-77

Villarrubia R, Oyagüez I, Alvarez-Roman MT, Mingot-Castellano ME, Parra R, Casado MA

 

 

Cost analysis of prophylaxis with activated prothrombin complex concéntrate versus on-demand therapy with activated factor VII in severe hemophilia A patients with inhibitors, in Spain
Haemophilia. 2015;21(3):320-9

Grande C, Abrisqueta P, Yébenes M, Sancho JM, Sánchez B, Martínez P, Lizuain M, Jarque I, Ríos E, García JA, López J, Canales M, Ramírez-Payer A, Rodríguez-Calvillo M, Do Nascimiento J, Suárez S, Dourdil MA, García JA, Buti M, Esteban R

Prevención de la reactivación del virus de la hepatitis b con tenofovir en pacientes anti-hbc positivo tratados con rituximab: resultados del estudio Preblin
LVI Congreso Nacional de la SEHH y XXXI Congreso Nacional de la SETH. Madrid, España. 6-8 nov 2014

Sabater E, Rueda A, Salar A, López-Guillermo A, Oyagüez I, Collar JM

 

 

Cost-effectiveness analysis of bendamustine plus rituximab as first-line treatment for patients with folicular lymphoma. Preliminary results
19th Congress of European Hematology Association (EHA). Milan, Italia. 12-15 jun 2014

Villarrubia R, Oyagüez I, Álvarez MT, Mingot ME, Parra R, Casado MA

 

 

Cost analysis of bypassing agent prophylaxis treatment versus on-demand therapy in hemophilia a with inhibitor in Spain
16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013

POSTER